Yiyun Huang Selected Research

Alcoholism (Alcohol Abuse)

3/2024	Imaging a putative marker of brain cortisol regulation in alcohol use disorder.
1/2022	Differences in the association between kappa opioid receptors and pain among Black and White adults with alcohol use disorders.
1/2021	Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving.
12/2019	Binge alcohol use is not associated with alterations in striatal dopamine receptor binding or dopamine release.
12/2019	The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving.
1/2019	Novel Kappa Opioid Receptor Agonist as Improved PET Radiotracer: Development and in Vivo Evaluation.
12/2018	PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age.
2/2016	Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050.
1/2016	PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo.
3/2013	Synthesis and evaluation of 11C-LY2795050 as a κ-opioid receptor antagonist radiotracer for PET imaging.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yiyun Huang Research Topics

Disease

18	Alzheimer Disease (Alzheimer's Disease) 04/2024 - 01/2010
18	Schizophrenia (Dementia Praecox) 01/2020 - 05/2002
15	Alcoholism (Alcohol Abuse) 03/2024 - 11/2005
12	Cognitive Dysfunction 04/2024 - 01/2016
10	Neoplasms (Cancer) 01/2023 - 07/2013
8	Substance-Related Disorders (Drug Abuse) 12/2019 - 01/2010
7	Mental Disorders (Mental Disorder) 01/2023 - 03/2005
6	Parkinson Disease (Parkinson's Disease) 02/2024 - 01/2014
6	Wounds and Injuries (Trauma) 10/2021 - 09/2011
5	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 10/2021 - 09/2011
4	Brain Neoplasms (Brain Tumor) 09/2023 - 07/2013
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 12/2013
4	Cocaine-Related Disorders (Cocaine Addiction) 01/2019 - 06/2004
4	Anxiety Disorders (Anxiety Disorder) 01/2017 - 12/2002
4	Major Depressive Disorder (Major Depressive Disorders) 11/2014 - 02/2004
3	Glioblastoma (Glioblastoma Multiforme) 01/2023 - 07/2013
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 01/2016
3	Epilepsy (Aura) 10/2020 - 12/2012
3	Ischemia 01/2019 - 12/2012
3	Hypoxia (Hypoxemia) 01/2018 - 06/2015
2	Inflammation (Inflammations) 11/2022 - 10/2015
2	Treatment-Resistant Depressive Disorder 04/2022 - 01/2017
2	Pain (Aches) 01/2022 - 01/2016
2	Dementia (Dementias) 01/2022 - 01/2020
2	Stroke (Strokes) 01/2022 - 01/2019
2	Spinal Cord Injuries (Spinal Cord Injury) 01/2022 - 11/2011
2	Obesity 01/2021 - 01/2020
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 10/2018
2	Central Nervous System Diseases (CNS Diseases) 01/2019 - 01/2018
2	Seizures (Absence Seizure) 02/2016 - 03/2005
2	Substance Withdrawal Syndrome (Withdrawal Symptoms) 05/2015 - 08/2014
2	Opioid-Related Disorders (Opiate Addiction) 05/2015 - 08/2014
2	Neuralgia (Stump Neuralgia) 01/2014 - 12/2012
2	Mood Disorders (Mood Disorder) 04/2013 - 12/2006
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 02/2023
1	Disease Progression 01/2023
1	Neuroinflammatory Diseases 01/2023
1	Pregnancy Complications 01/2023
1	Machado-Joseph Disease (Spinocerebellar Ataxia Type 3) 01/2023
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 12/2022
1	Tobacco Use Disorder (Nicotine Dependence) 10/2022

Drug/Important Bio-Agent (IBA)

17	Dopamine (Intropin)FDA LinkGeneric 11/2022 - 11/2005
12	Glycoproteins (Glycoprotein)IBA 01/2024 - 10/2018
9	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2016
9	Serotonin (5 Hydroxytryptamine)IBA 01/2022 - 12/2002
7	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 01/2022 - 06/2005
7	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2022 - 03/2005
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2011
7	Opioid Receptors (Opioid Receptor)IBA 01/2019 - 04/2013
5	Amyloid (Amyloid Fibrils)IBA 04/2024 - 01/2018
5	Glutamic Acid (Glutamate)FDA Link 01/2020 - 12/2012
4	Hydrocortisone (Cortisol)FDA LinkGeneric 03/2024 - 11/2014
4	Opioid Analgesics (Opioids)IBA 01/2022 - 08/2014
4	ErbB Receptors (EGF Receptor)IBA 01/2021 - 12/2013
4	Cocaine (Cocaine HCl)IBA 01/2021 - 06/2004
4	Amphetamine (Amfetamine)FDA LinkGeneric 04/2015 - 11/2005
3	Metabotropic Glutamate 5 ReceptorIBA 04/2024 - 08/2013
3	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 02/2024 - 01/2014
3	Naltrexone (ReVia)FDA LinkGeneric 01/2022 - 12/2019
3	EnzymesIBA 10/2021 - 01/2016
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 12/2013
3	Phosphotransferases (Kinase)IBA 01/2021 - 12/2013
3	CannabinoidsIBA 12/2020 - 12/2012
3	Antipsychotic Agents (Antipsychotics)IBA 01/2020 - 03/2010
3	fluoromisonidazoleIBA 01/2018 - 06/2015
3	5-HT1A Serotonin ReceptorIBA 06/2011 - 12/2006
2	3- amino- 4- (2- dimethylaminomethylphenylsulfanyl)benzonitrileIBA 02/2023 - 06/2005
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 12/2022 - 01/2022
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 04/2017
2	naxagolideIBA 01/2021 - 01/2020
2	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 01/2020 - 02/2004
2	Dopamine D3 ReceptorsIBA 10/2016 - 01/2016
2	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 03/2016 - 01/2014
2	Neuroprotective AgentsIBA 03/2016 - 01/2014
2	Glycine Plasma Membrane Transport ProteinsIBA 03/2016 - 12/2015
2	Anticonvulsants (Antiepileptic Drugs)IBA 02/2016 - 01/2016
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2016 - 10/2014
2	Therapeutic UsesIBA 05/2015 - 08/2014
2	TabletsIBA 05/2015 - 01/2014
2	Morphine (MS Contin)FDA LinkGeneric 05/2015 - 08/2014
2	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 10/2014 - 12/2012
2	3- (6- methylpyridin- 2- ylethynyl)cyclohex- 2- enone- O- methyloximeIBA 01/2014 - 08/2013
2	N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamideIBA 06/2011 - 12/2006
2	McN 5652IBA 01/2006 - 12/2002
1	florbetapirIBA 04/2024
1	neuromelaninIBA 02/2024
1	sigma-2 receptorIBA 09/2023
1	SAM-760IBA 02/2023
1	Glycogen Synthase Kinase 3IBA 01/2023
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023
1	imidazoleIBA 01/2023
1	Macrophage Colony-Stimulating FactorIBA 01/2023
1	veliparibIBA 01/2023
1	SDMIBA 01/2023
1	SmokeIBA 01/2023
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023
1	LipopolysaccharidesIBA 11/2022

Therapy/Procedure

6	Therapeutics 01/2024 - 07/2013
6	Drug Therapy (Chemotherapy) 01/2019 - 07/2013
3	Chinese Traditional Medicine (Traditional Chinese Medicine) 05/2015 - 01/2014